Global Leukapheresis Market

Global Leukapheresis Market Definition & Scope The Global Leukapheresis Market, valued at USD 0.11 Billion in 2025, is projected to reach USD 0.24 Billion by 2036, expanding at a CAGR of 7.26% during the forecast period. Leukapheresis is a specialized blood separation process that removes white blood cells (leukocytes) from whole blood and returns the other blood components to the donor or patient. This technology is an important cell harvesting method for research, regenerative medicine, immunotherapy, stem cell transplantation and production of advanced cell and gene therapies such as CAR-T cell therapies, and plays a major role in therapeutic treatment of hematological disorders. The market consists of leukapheresis devices and disposable consumables and is served by hospitals and clinics, blood centers, academic and research institutes and other healthcare and biotechnology organizations. The market is driven by increasing prevalence of leukemia and other hematological disorders, increasing development of cell and gene therapies, rising demand for hematopoietic stem cell transplantation and growing investments in immunotherapy research. Improvements in procedural efficiency, donor safety, and therapeutic outcomes are being realized through ongoing advancements in automated apheresis systems, improved disposable technologies, and the expansion of clinical research activities. The World Health Organization (WHO) reports that the global burden of hematological cancers is increasing, leading to increased demand for sophisticated blood component separation technologies used in diagnosis, treatment and cellular therapy manufacturing. The global leukapheresis market is expected to witness significant long-term growth opportunities over the forecast period, driven by the increasing adoption of CAR-T therapies, personalized medicine, regenerative medicine, and biopharmaceutical research. Global Leukapheresis Market: Key Highlights • The Global Leukapheresis Market was valued at USD 0.11 billion in 2025. The growth is driven by increasing prevalence of hematological disorders, expanding adoption of cell and gene therapies, growing demand for hematopoietic stem cell transplantation and rising investments in immunotherapy research. • The market is anticipated to reach USD 0.24 billion in 2036 and is projected to grow at a CAGR of 7.26% from 2026 to 2036. Growth is driven by increased clinical adoption of CAR-T cell therapies, technological advancements in automated apheresis, regenerative medicine expansion, and increasing research in immune cell collection. • North America is the leading region in the global market with an estimated share of 42.4% in 2025. The region offers a sophisticated healthcare infrastructure, robust biotechnology and biopharmaceutical industries, high adoption of cell therapies, active clinical research, and favorable reimbursement for specialized therapeutic procedures. • The Asia Pacific is expected to witness the fastest CAGR of 8.4% during the forecast period 2026-2036 owing to expanding healthcare infrastructure, increasing investments in biotechnology, increasing stem cell research, rising cancer burden, and increasing manufacturing capacity for advanced cell therapies in countries such as China, Japan, South Korea, and India. • Product segment (The disposables dominate the product segment with an estimated 63.7% of the market share in 2025) Single-use clinical protocols, high procedural volumes, infection prevention needs, regulatory compliance, and the ongoing demand created by each leukapheresis procedure all contribute to their dominance. • Devices are projected to register the highest CAGR of 7.9% over the forecast period due to rising adoption of automated apheresis systems, technological advancements in blood component separation, and increasing installations in hospitals, blood centers, and research facilities. • Therapeutic applications are expected to constitute an estimated share of around 69.1% in 2025, due to the growing use of leukapheresis as a treatment of leukemia, hyperleukocytosis, autoimmune disorders, and as a preparatory step in cell-based therapy. • Research applications are set to record the highest CAGR of 8.7% during 2026-2036. This can be attributed to the growing investments in immunology research, regenerative medicine, stem cell biology, gene editing, and clinical development of next generation cellular therapies. • Hospitals & Clinics is the leading end-user segment holding an estimated 56.4% share in 2025 due to the existence of specialized hematology departments, oncology centers, transplant programs, and advanced apheresis infrastructure. • The fastest CAGR of 8.9% is anticipated in the Academic & Research Institutes segment over the forecast period, driven by the rising number of clinical trials, growing research in cell and gene therapy, government funding for biomedical innovation, and increasing partnerships between academic institutions and biotechnology companies. Research Scope & Methodology This study provides a comprehensive strategic assessment of the Global Leukapheresis Market across the forecast period of 2026–2036. The report covers market size, revenue forecast, competitive landscape, technological advancements, regulatory developments, adoption of cell therapy, and potential investment opportunities impacting the global leukapheresis market. The analysis includes the entire value chain from the manufacture of apheresis devices, disposable kit manufacture, blood component separation technologies, cell collection services, clinical applications, research usage, distribution and healthcare implementation of hospitals, blood centers, academic institutions, biotechnology companies and research organizations. Market is analyzed by Product (Devices, Disposables), Application (Therapeutic, Research) & End User (Hospitals & Clinics, Blood Centers, Academic & Research Institutes, Others). The regional analysis includes North America, Europe, Asia Pacific, and LAMEA, with the assessments on healthcare infrastructure, the presence of hematology treatment options, the adoption of cell and gene therapy, biotechnology investments, the regulatory landscape, and the clinical research activity that impact the growth of the regional market. The report also covers progress in automated apheresis technologies, CAR-T cell manufacturing, stem cell transplantation, regenerative medicine, personalized therapies and blood component separation systems that continue to impact the competitive landscape of the leukapheresis market. The research methodology is a combination of extensive primary and secondary research which gives the market intelligence with the best coverage. Primary research is based on structured interviews with hematologists, oncologists, transfusion medicine specialists, hospital administrators, blood center operators, biotechnology companies, medical device manufacturers, research organizations, regulatory experts and industry consultants in major global markets. Secondary research comprises international healthcare organization publications, government agencies, annual reports, investor presentations, scientific journals, regulatory databases, hematology associations and validated sources for market intelligence. Market estimates are based on a combination of top-down and bottom-up approaches, and are validated through data triangulation to ensure consistency across all market segments and regional analyses. Forecast models incorporate historical volumes of procedures, incidence of cancer, trends in stem cell transplantation, uptake of cell therapy, healthcare spending, biotechnology investment, regulatory approvals, demographic trends, and technological innovation. A competitive benchmarking of product portfolios, automation capabilities, disposable technologies, research and development investments, manufacturing capacity, strategic partnerships, regulatory approvals and geographic presence of key market players provides a comprehensive understanding of the changing competitive landscape within the Global Leukapheresis Market. Key Market Segments By Product: Devices Disposables By Application: Therapeutic Research By End User: Hospitals & Clinics Blood Centers Academic & Research Institutes Others Key Market Players Charles River Laboratories International, Inc. Adacyte Therapeutics Haemonetics Corporation Guangzhou Daji Medical Science PuriBlood Medical Co., Ltd. Cerus Corporation SB-Kawasumi Laboratories, Inc. StemExpress, LLC. Haemonetics Corporation Lonza Group AG Industry Trends • Leukocyte collection is the key first step in the manufacture of advanced therapies such as CAR-T cells, T-cell receptor (TCR) therapies, natural killer (NK) cell therapies and gene-edited cellular products. As such, cell and gene therapy development is emerging as the key growth driver for the leukapheresis market. The clinical pipeline is expanding rapidly, driving demand for high-quality leukapheresis. • Automation is changing leukapheresis systems with advanced apheresis platforms that improve collection efficiency, reduce procedure time, increase donor comfort and ensure consistent quality of cell collection. Now, with modern automated systems, we can get better consistency in both therapeutic applications and in the manufacturing of cell therapies. • The commercialization of CAR-T therapies is increasing, and this is driving demand for leukapheresis services. Cellular immunotherapies are gaining popularity and hospitals, specialized collection centers and contract development and manufacturing organizations (CDMOs) are increasing leukapheresis capabilities to facilitate commercial production as regulatory approvals continue to increase globally. • The growing field of regenerative medicine and stem cell transplantation continues to drive the importance of leukapheresis technologies. The collection of peripheral blood stem and immune cells is still important for hematopoietic stem cell transplantation, regenerative therapies and immune reconstitution treatments. • To ensure dependable access to high-quality starting cellular material for clinical trials and commercial manufacturing, biotechnology companies are increasingly building dedicated leukapheresis collection networks and strategic partnerships with hospitals and blood centers. • The growing importance of single-use disposable kits is still being driven by the stringent infection prevention protocols, reduced cross-contamination risks, simplified regulatory compliance and improved procedural safety. Recurrent revenue growth across the industry is driven by increasing demand for disposable technologies. • The increasing number of decentralized cell therapy manufacturing models is driving the demand for standardized leukapheresis procedures in geographically distributed healthcare facilities. Standardisation of collection protocols is increasingly important to ensure that the quality of the product is consistent across all manufacturing sites. • Artificial intelligence (AI) and digital data management are increasingly being incorporated into apheresis workflows to enhance scheduling, donor selection, procedure monitoring, quality assurance, and inventory management. Digital platforms are improving operational efficiency and supporting regulatory documentation needs. • With growing clinical research in immunology, oncology, autoimmune diseases and rare genetic disorders, the use of leukapheresis is expanding beyond traditional therapeutic applications. Leukocyte collection is being done by research institutions to find biomarkers, translational medicine, and next-generation immunotherapies. • Leukapheresis innovation continues to be driven by strategic alliances across the ecosystem between biotechnology companies, medical device manufacturers, academic research organizations, contract manufacturing organizations and healthcare providers. Investments in automated collection technologies, advanced disposables, cell processing platforms and personalized medicine are expected to drive long-term growth of the global leukapheresis market. Market Determinants • Growing Adoption of Cell and Gene Therapies: The rapid expansion of cell and gene therapies, particularly CAR-T cell therapies, T-cell receptor (TCR) therapies, and natural killer (NK) cell therapies, is a major driver of the leukapheresis market. Leukapheresis serves as the critical first step in collecting immune cells required for manufacturing these advanced therapies. Increasing regulatory approvals and expanding clinical pipelines are significantly boosting demand for leukapheresis procedures. • Rising Incidence of Hematological Disorders and Cancer: Increasing prevalence of leukemia, lymphoma, multiple myeloma, and other hematological diseases is driving demand for therapeutic leukapheresis and stem cell transplantation. According to the World Health Organization (WHO), the growing global burden of cancer continues to increase the need for advanced blood component separation technologies used in diagnosis, treatment, and cellular therapy manufacturing. • Expansion of Stem Cell Transplantation and Regenerative Medicine: Growing utilization of hematopoietic stem cell transplantation and regenerative medicine is supporting market growth. Leukapheresis plays a crucial role in collecting peripheral blood stem cells and immune cells for transplantation procedures, tissue regeneration, and advanced immunotherapies. • Technological Advancements in Automated Apheresis Systems: Continuous innovation in automated leukapheresis devices, improved blood component separation technologies, enhanced donor safety features, and digital workflow integration is improving collection efficiency, reducing procedure times, and increasing procedural reliability across hospitals and blood centers. • High Procedure Costs and Specialized Infrastructure Requirements: Leukapheresis procedures require advanced apheresis equipment, trained healthcare professionals, specialized collection facilities, and stringent quality control measures. High capital investment and operational costs may limit adoption, particularly in developing healthcare systems with constrained budgets. • Complex Regulatory and Quality Compliance Standards: Collection of cellular products intended for therapeutic use is subject to rigorous regulatory requirements, including Good Manufacturing Practice (GMP), quality assurance, traceability, donor screening, and product handling standards. Compliance with evolving regulatory frameworks increases operational complexity and costs for healthcare providers, biotechnology companies, and collection centers. Opportunity Mapping Based on Market Trends • Expansion of Cell and Gene Therapy Manufacturing: The rapid commercialization of CAR-T cell therapies, gene-edited therapies, natural killer (NK) cell therapies, and other advanced cellular therapies is creating substantial opportunities for the leukapheresis market. Increasing demand for high-quality immune cell collection is encouraging healthcare providers, biotechnology companies, and contract development and manufacturing organizations (CDMOs) to expand leukapheresis infrastructure and collection capabilities. • Growing Investments in Regenerative Medicine and Clinical Research: Rising investments in regenerative medicine, stem cell research, immunology, and translational medicine are creating new growth opportunities for leukapheresis technologies. Increasing numbers of clinical trials involving cellular immunotherapies and regenerative treatments are expected to drive demand for reliable leukocyte collection systems and specialized research services. • Technological Advancements in Automated Apheresis Systems: Continuous innovation in automated blood component separation technologies, digital workflow management, artificial intelligence-assisted monitoring, and single-use disposable systems is improving collection efficiency, donor safety, and procedural standardization. Manufacturers introducing next-generation automated leukapheresis platforms are well positioned to capitalize on growing clinical and research demand. • Expansion of Biotechnology Infrastructure Across Emerging Economies: Increasing investments in biotechnology manufacturing, cancer treatment centers, stem cell transplantation programs, and advanced healthcare infrastructure across Asia Pacific, Latin America, the Middle East, and Africa are creating favorable conditions for market expansion. Government support for biotechnology innovation, precision medicine, and cellular therapy development is expected to generate long-term opportunities for leukapheresis equipment manufacturers and service providers. Value-Creating Segments and Growth Pockets By Product, the Global Leukapheresis Market is segmented into Devices and Disposables. The disposables segment is expected to dominate the market by product with an estimated share of 63.7% in 2025. The segment is driven by the recurring use of collection kits, filters and accessories required for each leukapheresis procedure, and single-use tubing sets. Sustained demand for disposable products continues to be supported by stringent infection control protocols, regulatory compliance and the increasing volume of therapeutic and research procedures. The devices are projected to register the highest CAGR of 7.9% between 2026 and 2036, aided by rising adoption of automated apheresis systems, technological advancements in blood component separation, and increasing installations in hospitals, blood centers, and cell therapy manufacturing facilities. Automation improvements, collection efficiency gains, and procedural accuracy increases will drive market growth. By Application, the Global Leukapheresis Market is segmented into Therapeutic and Research. Therapeutic is expected to dominate the market with an estimated share of 69.1% in 2025. The segment’s growth is attributed to the increasing use of leukapheresis for the management of leukemia, hyperleukocytosis, autoimmune diseases, and hematological disorders. It also plays an important role in the collection of immune cells for approved cell-based therapies and stem cell transplantation. Research is projected to experience the highest CAGR of 8.7% during 2026–2036 due to rising investments in immunology, regenerative medicine, gene editing, stem cell biology and next-generation cellular therapy development. The growth of this segment is further driven by increasing clinical trial activity and rising collaboration between academia and biotechnology companies By End User, the Global Leukapheresis Market is segmented into Hospitals & Clinics, Blood Centers, Academic & Research Institutes, and Others. The segment Hospitals & Clinics is projected to account for the largest market share, with an estimated 56.4% in 2025. The segment includes specialized hematology and oncology services, stem cell transplantation programs, advanced apheresis capabilities and high patient volumes with therapeutic leukapheresis procedures and immune cell collection. Academic & Research Institutes are anticipated to witness the highest CAGR of 8.9% over the forecast period 2026–2036, owing to increasing funding for biomedical research, rising number of cell and gene therapy clinical trials, growing demand for translational medicine, and rising collaborations with biotechnology firms engaged in the development of novel cellular immunotherapies and regenerative medicine solutions. Regional Market Assessment North America North America is expected to dominate the global leukapheresis market accounting for an estimated share of 42.4% in 2025. The region’s leadership is bolstered by advanced healthcare infrastructure, broad access to cell and gene therapies, a vibrant biotech ecosystem, and strong emphasis on clinical research. The US leads the regional market due to the presence of leading CAR-T therapy developers, well-established stem cell transplantation programs, advanced apheresis facilities and favorable reimbursement for specialized therapeutic procedures. Regional Market Growth Is Strengthened by Continuous Investment in Precision Medicine and Regenerative Medicine. Europe Europe is a significant market for leukapheresis owing to its robust healthcare infrastructure, growing hematology and oncology treatment programs, as well as rising investments in advanced cellular therapies. Germany, the United Kingdom, France, Italy and Switzerland are continuing to upgrade their infrastructure for stem cell transplantation, clinical research capacity and biotechnology innovation. In addition, the market is further driven by the surging regulatory support for advanced therapy medicinal products (ATMPs). Asia Pacific The Asia Pacific is expected to record the fastest CAGR of 8.4% during the forecast period 2026-2036. The growth in the region is attributed to increasing biotechnology manufacturing, rising cancer incidence, growing stem cell transplantation programs, increasing investments in cell and gene therapy development, and improving healthcare infrastructure across China, Japan, South Korea, India, and Southeast Asia. Government initiatives to foster innovation in biotechnology and regenerative medicine are anticipated to speed up the regional market growth. LAMEA The LAMEA is expected to be a promising market for leukapheresis due to the improving healthcare infrastructure, growing oncology treatment facilities, increasing investments in biotechnology and rising awareness of advanced cellular therapies. Countries like Brazil, Mexico, Saudi Arabia, United Arab Emirates, and South Africa are improving hematology services, blood collection infrastructure, and clinical research capabilities to improve access to advanced therapeutic procedures and precision medicine. Recent Developments • May 2025: Haemonetics Corporation expanded its automated apheresis technology portfolio with enhanced collection systems designed to improve procedural efficiency, donor safety, and cell collection quality for therapeutic and cell therapy applications. • March 2025: Lonza Group AG strengthened its cell and gene therapy manufacturing capabilities by expanding integrated leukapheresis-to-manufacturing solutions supporting commercial CAR-T and advanced cellular therapy production. • October 2024: Cerus Corporation advanced collaborations with healthcare organizations to improve blood component processing technologies and strengthen support for specialized cellular therapy workflows. • July 2024: StemExpress, LLC. expanded its human cell collection network to support increasing demand for high-quality leukapheresis products used in immunology research, regenerative medicine, and clinical development programs. Critical Business Questions Addressed How will the Global Leukapheresis Market evolve through 2036? The report evaluates long-term market growth, expansion of cell and gene therapies, regenerative medicine, stem cell transplantation, technological innovation, and clinical research trends shaping future demand for leukapheresis technologies. Which product, application, and end-user segments will generate the greatest commercial opportunities? The study identifies the dominant and fastest-growing market segments, enabling medical device manufacturers, biotechnology companies, healthcare providers, and investors to prioritize strategic investments. What are the primary factors driving market expansion? The report analyzes the influence of hematological disease prevalence, CAR-T therapy commercialization, stem cell transplantation, regenerative medicine, biotechnology investments, and automation in apheresis technologies on future market development. Which regional markets present the strongest long-term investment potential? The assessment compares biotechnology infrastructure, healthcare capabilities, cell therapy adoption, research activity, regulatory environments, and healthcare investments across major regions to identify the most attractive growth opportunities. How can leukapheresis companies strengthen their competitive position in the evolving industry? The report examines strategic priorities including automated apheresis innovation, disposable technology development, cell therapy manufacturing partnerships, biotechnology collaborations, research investments, and expansion of collection infrastructure to support long-term competitive advantage. Beyond the Forecast • The leukapheresis market will increasingly benefit from advances in cell and gene therapy manufacturing, automated apheresis systems, regenerative medicine, artificial intelligence-assisted workflow optimization, and personalized medicine, enabling more efficient and standardized immune cell collection. • Rising commercialization of CAR-T therapies, expanding stem cell transplantation programs, increasing investments in biotechnology research, and continued growth of regenerative medicine will create substantial opportunities for leukapheresis equipment manufacturers, disposable suppliers, and specialized collection service providers across developed and emerging markets. • As healthcare systems prioritize precision medicine, advanced cellular therapies, and translational research, companies investing in next-generation apheresis technologies, integrated cell collection platforms, digital workflow management, and strategic biotechnology partnerships will be well positioned to capitalize on long-term growth opportunities in the global leukapheresis market through 2036.